Therefore, there are three potential underlying reasons for the therapeutic failure in the present case: first, a high-risk patient with protein S deficiency; second, uncertain edoxaban efficacy in the presence of an intracardiac device; and third, uncertain edoxaban efficacy in a patient with normal renal function. The gene discussed is PROS1; the disease is hyperinsulinemic hypoglycemia, familial, 4.